Selected research
Market Structure
Global Sickle Cell Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Sickle Cell Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Sickle Cell Disease Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Sickle Cell Disease Drug include Global Blood Therapeutics Inc, Gilead Sciences Inc, Genethon SA, Gamida Cell Ltd, Errant Gene Therapeutics LLC, Editas Medicine Inc, Daiichi Sankyo Co Ltd, CSL Ltd and CRISPR Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Sickle Cell Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Sickle Cell Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Sickle Cell Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sickle Cell Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Sickle Cell Disease Drug Segment by Company
Global Blood Therapeutics Inc
Gilead Sciences Inc
Genethon SA
Gamida Cell Ltd
Errant Gene Therapeutics LLC
Editas Medicine Inc
Daiichi Sankyo Co Ltd
CSL Ltd
CRISPR Therapeutics
Calimmune Inc
Bristol-Myers Squibb Co
bluebird bio Inc
Bioverativ Inc
Bio Products Laboratory Ltd
ArQule Inc
Annexin Pharmaceuticals AB
Angiocrine Bioscience Inc
Addmedica SAS
Acceleron Pharma Inc
Sickle Cell Disease Drug Segment by Type
CAL-H
DRX-194
CTX-001
BIVV-003
ARQ-092
Others
Sickle Cell Disease Drug Segment by Application
Hospital
Clinic
Others
Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Sickle Cell Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Sickle Cell Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Sickle Cell Disease Drug Industry Trends
Table 2. Sickle Cell Disease Drug Industry Drivers
Table 3. Sickle Cell Disease Drug Industry Opportunities and Challenges
Table 4. Sickle Cell Disease Drug Industry Restraints
Table 5. Global Sickle Cell Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Sickle Cell Disease Drug Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Sickle Cell Disease Drug Sales by Manufacturers (K Units) & (2021-2026)
Table 8. Global Sickle Cell Disease Drug Sales Market Share by Manufacturers
Table 9. Global Sickle Cell Disease Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026)
Table 10. Global Sickle Cell Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Sickle Cell Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Sickle Cell Disease Drug Manufacturers, Product Type & Application
Table 13. Global Sickle Cell Disease Drug Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Sickle Cell Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of CAL-H
Table 17. Major Manufacturers of DRX-194
Table 18. Major Manufacturers of CTX-001
Table 19. Major Manufacturers of BIVV-003
Table 20. Major Manufacturers of ARQ-092
Table 21. Major Manufacturers of Others
Table 22. Global Sickle Cell Disease Drug Sales by Type 2021 VS 2025 VS 2032 (K Units)
Table 23. Global Sickle Cell Disease Drug Sales by Type (2021-2026) & (K Units)
Table 24. Global Sickle Cell Disease Drug Sales by Type (2027-2032) & (K Units)
Table 25. Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2026)
Table 26. Global Sickle Cell Disease Drug Sales Market Share by Type (2027-2032)
Table 27. Global Sickle Cell Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units)
Table 28. Global Sickle Cell Disease Drug Revenue by Type (2021-2026) & (K Units)
Table 29. Global Sickle Cell Disease Drug Revenue by Type (2027-2032) & (K Units)
Table 30. Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2026)
Table 31. Global Sickle Cell Disease Drug Revenue Market Share by Type (2027-2032)
Table 32. Major Manufacturers of Hospital
Table 33. Major Manufacturers of Clinic
Table 34. Major Manufacturers of Others
Table 35. Global Sickle Cell Disease Drug Sales by Application 2021 VS 2025 VS 2032 (K Units)
Table 36. Global Sickle Cell Disease Drug Sales by Application (2021-2026) & (K Units)
Table 37. Global Sickle Cell Disease Drug Sales by Application (2027-2032) & (K Units)
Table 38. Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2026)
Table 39. Global Sickle Cell Disease Drug Sales Market Share by Application (2027-2032)
Table 40. Global Sickle Cell Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units)
Table 41. Global Sickle Cell Disease Drug Revenue by Application (2021-2026) & (K Units)
Table 42. Global Sickle Cell Disease Drug Revenue by Application (2027-2032) & (K Units)
Table 43. Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2026)
Table 44. Global Sickle Cell Disease Drug Revenue Market Share by Application (2027-2032)
Table 45. Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units)
Table 46. Global Sickle Cell Disease Drug Sales by Region (2021-2026) & (K Units)
Table 47. Global Sickle Cell Disease Drug Sales Market Share by Region (2021-2026)
Table 48. Global Sickle Cell Disease Drug Sales Forecasted by Region (2027-2032) & (K Units)
Table 49. Global Sickle Cell Disease Drug Sales Forecasted Market Share by Region (2027-2032)
Table 50. North America Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 51. North America Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 52. North America Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units)
Table 53. Europe Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 54. Europe Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 55. Europe Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units)
Table 56. Asia Pacific Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 57. Asia Pacific Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 58. Asia Pacific Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units)
Table 59. South America, Middle East and Africa Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
Table 60. South America, Middle East and Africa Sickle Cell Disease Drug Sales by Country (2021-2026) & (K Units)
Table 61. South America, Middle East and Africa Sickle Cell Disease Drug Sales by Country (2027-2032) & (K Units)
Table 62. Global Sickle Cell Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 63. Global Sickle Cell Disease Drug Revenue by Region (2021-2026) & (US$ Million)
Table 64. Global Sickle Cell Disease Drug Revenue by Region (2027-2032) & (US$ Million)
Table 65. Global Sickle Cell Disease Drug Revenue Market Share by Region (2021-2026)
Table 66. Global Sickle Cell Disease Drug Revenue Market Share by Region (2027-2032)
Table 67. Global Blood Therapeutics Inc Company Information
Table 68. Global Blood Therapeutics Inc Business Overview
Table 69. Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 70. Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
Table 71. Global Blood Therapeutics Inc Recent Development
Table 72. Gilead Sciences Inc Company Information
Table 73. Gilead Sciences Inc Business Overview
Table 74. Gilead Sciences Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 75. Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
Table 76. Gilead Sciences Inc Recent Development
Table 77. Genethon SA Company Information
Table 78. Genethon SA Business Overview
Table 79. Genethon SA Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Genethon SA Sickle Cell Disease Drug Product Portfolio
Table 81. Genethon SA Recent Development
Table 82. Gamida Cell Ltd Company Information
Table 83. Gamida Cell Ltd Business Overview
Table 84. Gamida Cell Ltd Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 85. Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
Table 86. Gamida Cell Ltd Recent Development
Table 87. Errant Gene Therapeutics LLC Company Information
Table 88. Errant Gene Therapeutics LLC Business Overview
Table 89. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 90. Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
Table 91. Errant Gene Therapeutics LLC Recent Development
Table 92. Editas Medicine Inc Company Information
Table 93. Editas Medicine Inc Business Overview
Table 94. Editas Medicine Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 95. Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
Table 96. Editas Medicine Inc Recent Development
Table 97. Daiichi Sankyo Co Ltd Company Information
Table 98. Daiichi Sankyo Co Ltd Business Overview
Table 99. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 100. Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
Table 101. Daiichi Sankyo Co Ltd Recent Development
Table 102. CSL Ltd Company Information
Table 103. CSL Ltd Business Overview
Table 104. CSL Ltd Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 105. CSL Ltd Sickle Cell Disease Drug Product Portfolio
Table 106. CSL Ltd Recent Development
Table 107. CRISPR Therapeutics Company Information
Table 108. CRISPR Therapeutics Business Overview
Table 109. CRISPR Therapeutics Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 110. CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
Table 111. CRISPR Therapeutics Recent Development
Table 112. Calimmune Inc Company Information
Table 113. Calimmune Inc Business Overview
Table 114. Calimmune Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 115. Calimmune Inc Sickle Cell Disease Drug Product Portfolio
Table 116. Calimmune Inc Recent Development
Table 117. Bristol-Myers Squibb Co Company Information
Table 118. Bristol-Myers Squibb Co Business Overview
Table 119. Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 120. Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
Table 121. Bristol-Myers Squibb Co Recent Development
Table 122. bluebird bio Inc Company Information
Table 123. bluebird bio Inc Business Overview
Table 124. bluebird bio Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 125. bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
Table 126. bluebird bio Inc Recent Development
Table 127. Bioverativ Inc Company Information
Table 128. Bioverativ Inc Business Overview
Table 129. Bioverativ Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 130. Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
Table 131. Bioverativ Inc Recent Development
Table 132. Bio Products Laboratory Ltd Company Information
Table 133. Bio Products Laboratory Ltd Business Overview
Table 134. Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 135. Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
Table 136. Bio Products Laboratory Ltd Recent Development
Table 137. ArQule Inc Company Information
Table 138. ArQule Inc Business Overview
Table 139. ArQule Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 140. ArQule Inc Sickle Cell Disease Drug Product Portfolio
Table 141. ArQule Inc Recent Development
Table 142. Annexin Pharmaceuticals AB Company Information
Table 143. Annexin Pharmaceuticals AB Business Overview
Table 144. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 145. Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
Table 146. Annexin Pharmaceuticals AB Recent Development
Table 147. Angiocrine Bioscience Inc Company Information
Table 148. Angiocrine Bioscience Inc Business Overview
Table 149. Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 150. Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
Table 151. Angiocrine Bioscience Inc Recent Development
Table 152. Addmedica SAS Company Information
Table 153. Addmedica SAS Business Overview
Table 154. Addmedica SAS Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 155. Addmedica SAS Sickle Cell Disease Drug Product Portfolio
Table 156. Addmedica SAS Recent Development
Table 157. Acceleron Pharma Inc Company Information
Table 158. Acceleron Pharma Inc Business Overview
Table 159. Acceleron Pharma Inc Sickle Cell Disease Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 160. Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
Table 161. Acceleron Pharma Inc Recent Development
Table 162. Key Raw Materials
Table 163. Raw Materials Key Suppliers
Table 164. Sickle Cell Disease Drug Distributors List
Table 165. Sickle Cell Disease Drug Customers List
Table 166. Research Programs/Design for This Report
Table 167. Authors List of This Report
Table 168. Secondary Sources
Table 169. Primary Sources
List of Figures
Figure 1. Sickle Cell Disease Drug Product Image
Figure 2. Global Sickle Cell Disease Drug Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Sickle Cell Disease Drug Market Size (2021-2032) & (US$ Million)
Figure 4. Global Sickle Cell Disease Drug Sales (2021-2032) & (K Units)
Figure 5. Global Sickle Cell Disease Drug Average Price (US$/Unit) & (2021-2032)
Figure 6. Global Top 5 and 10 Sickle Cell Disease Drug Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. CAL-H Image
Figure 9. DRX-194 Image
Figure 10. CTX-001 Image
Figure 11. BIVV-003 Image
Figure 12. ARQ-092 Image
Figure 13. Others Image
Figure 14. Global Sickle Cell Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 15. Global Sickle Cell Disease Drug Sales Market Share 2021 VS 2025 VS 2032
Figure 16. Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2032)
Figure 17. Global Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
Figure 18. Global Sickle Cell Disease Drug Revenue Market Share 2021 VS 2025 VS 2032
Figure 19. Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032)
Figure 20. Hospital Image
Figure 21. Clinic Image
Figure 22. Others Image
Figure 23. Global Sickle Cell Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 24. Global Sickle Cell Disease Drug Sales Market Share 2021 VS 2025 VS 2032
Figure 25. Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2032)
Figure 26. Global Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
Figure 27. Global Sickle Cell Disease Drug Revenue Market Share 2021 VS 2025 VS 2032
Figure 28. Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032)
Figure 29. North America Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 30. North America Sickle Cell Disease Drug Sales Market Share by Country (2021-2032)
Figure 31. U.S. Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 32. Canada Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 33. Mexico Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 34. Europe Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 35. Europe Sickle Cell Disease Drug Sales Market Share by Country (2021-2032)
Figure 36. Germany Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 37. France Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 38. U.K. Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 39. Italy Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 40. Netherlands Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 41. Asia Pacific Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 42. Asia Pacific Sickle Cell Disease Drug Sales Market Share by Country (2021-2032)
Figure 43. China Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 44. Japan Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 45. South Korea Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 46. Southeast Asia Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 47. India Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 48. Australia Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 49. South America, Middle East and Africa Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 50. South America, Middle East and Africa Sickle Cell Disease Drug Sales Market Share by Country (2021-2032)
Figure 51. Brazil Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 52. South Africa Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 53. Saudi Arabia Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 54. Turkey Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 55. Argentina Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 56. UAE Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 57. Egypt Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 58. Chile Sickle Cell Disease Drug Sales and Growth Rate (2021-2032) & (K Units)
Figure 59. Global Sickle Cell Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 60. Global Sickle Cell Disease Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 61. North America Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million)
Figure 62. North America Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Europe Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million)
Figure 64. Europe Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. Asia-Pacific Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million)
Figure 66. Asia-Pacific Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. South America, Middle East and Africa Sickle Cell Disease Drug Revenue (2021-2032) & (US$ Million)
Figure 68. South America, Middle East and Africa Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 69. Sickle Cell Disease Drug Value Chain
Figure 70. Manufacturing Cost Structure
Figure 71. Sickle Cell Disease Drug Production Mode & Process
Figure 72. Direct Comparison with Distribution Share
Figure 73. Distributors Profiles
Figure 74. Years Considered
Figure 75. Research Process
Figure 76. Key Executives Interviewed
Scope & coverage.
Types
- CAL-H
- DRX-194
- CTX-001
- BIVV-003
- ARQ-092
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Global Blood Therapeutics Inc
- Gilead Sciences Inc
- Genethon SA
- Gamida Cell Ltd
- Errant Gene Therapeutics LLC
- Editas Medicine Inc
- Daiichi Sankyo Co Ltd
- CSL Ltd
- CRISPR Therapeutics
- Calimmune Inc
- Bristol-Myers Squibb Co
- bluebird bio Inc
- Bioverativ Inc
- Bio Products Laboratory Ltd
- ArQule Inc
- Annexin Pharmaceuticals AB
- Angiocrine Bioscience Inc
- Addmedica SAS
- Acceleron Pharma Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Sickle Cell Disease Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Sickle Cell Disease Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Sickle Cell Disease Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Sickle Cell Disease Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Sickle Cell Disease Drug Market Dynamics
- 2.1 Sickle Cell Disease Drug Industry Trends
- 2.2 Sickle Cell Disease Drug Industry Drivers
- 2.3 Sickle Cell Disease Drug Industry Opportunities and Challenges
- 2.4 Sickle Cell Disease Drug Industry Restraints
3 Sickle Cell Disease Drug Market by Manufacturers
- 3.1 Global Sickle Cell Disease Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Sickle Cell Disease Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Sickle Cell Disease Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Sickle Cell Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Sickle Cell Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Sickle Cell Disease Drug Manufacturers, Product Type & Application
- 3.7 Global Sickle Cell Disease Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Sickle Cell Disease Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Sickle Cell Disease Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Sickle Cell Disease Drug Tier 1, Tier 2, and Tier 3
4 Sickle Cell Disease Drug Market by Type
- 4.1 Sickle Cell Disease Drug Type Introduction
- 4.1.1 CAL-H
- 4.1.2 DRX-194
- 4.1.3 CTX-001
- 4.1.4 BIVV-003
- 4.1.5 ARQ-092
- 4.1.6 Others
- 4.2 Global Sickle Cell Disease Drug Sales by Type
- 4.2.1 Global Sickle Cell Disease Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Sickle Cell Disease Drug Sales by Type (2021-2032)
- 4.2.3 Global Sickle Cell Disease Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Sickle Cell Disease Drug Revenue by Type
- 4.3.1 Global Sickle Cell Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Sickle Cell Disease Drug Revenue by Type (2021-2032)
- 4.3.3 Global Sickle Cell Disease Drug Revenue Market Share by Type (2021-2032)
5 Sickle Cell Disease Drug Market by Application
- 5.1 Sickle Cell Disease Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Others
- 5.2 Global Sickle Cell Disease Drug Sales by Application
- 5.2.1 Global Sickle Cell Disease Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Sickle Cell Disease Drug Sales by Application (2021-2032)
- 5.2.3 Global Sickle Cell Disease Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Sickle Cell Disease Drug Revenue by Application
- 5.3.1 Global Sickle Cell Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Sickle Cell Disease Drug Revenue by Application (2021-2032)
- 5.3.3 Global Sickle Cell Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Sickle Cell Disease Drug Sales by Region
- 6.1 Global Sickle Cell Disease Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Sickle Cell Disease Drug Sales by Region (2021-2032)
- 6.2.1 Global Sickle Cell Disease Drug Sales by Region (2021-2026)
- 6.2.2 Global Sickle Cell Disease Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Sickle Cell Disease Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Sickle Cell Disease Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Sickle Cell Disease Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Sickle Cell Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Sickle Cell Disease Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Sickle Cell Disease Drug Revenue by Region
- 7.1 Global Sickle Cell Disease Drug Revenue by Region
- 7.1.1 Global Sickle Cell Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Sickle Cell Disease Drug Revenue by Region (2021-2026)
- 7.1.3 Global Sickle Cell Disease Drug Revenue by Region (2027-2032)
- 7.1.4 Global Sickle Cell Disease Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Sickle Cell Disease Drug Revenue (2021-2032)
- 7.2.2 North America Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Sickle Cell Disease Drug Revenue (2021-2032)
- 7.3.2 Europe Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Sickle Cell Disease Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Sickle Cell Disease Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Sickle Cell Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Global Blood Therapeutics Inc
- 8.1.1 Global Blood Therapeutics Inc Company Information
- 8.1.2 Global Blood Therapeutics Inc Business Overview
- 8.1.3 Global Blood Therapeutics Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Global Blood Therapeutics Inc Sickle Cell Disease Drug Product Portfolio
- 8.1.5 Global Blood Therapeutics Inc Recent Developments
- 8.2 Gilead Sciences Inc
- 8.2.1 Gilead Sciences Inc Company Information
- 8.2.2 Gilead Sciences Inc Business Overview
- 8.2.3 Gilead Sciences Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Gilead Sciences Inc Sickle Cell Disease Drug Product Portfolio
- 8.2.5 Gilead Sciences Inc Recent Developments
- 8.3 Genethon SA
- 8.3.1 Genethon SA Company Information
- 8.3.2 Genethon SA Business Overview
- 8.3.3 Genethon SA Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Genethon SA Sickle Cell Disease Drug Product Portfolio
- 8.3.5 Genethon SA Recent Developments
- 8.4 Gamida Cell Ltd
- 8.4.1 Gamida Cell Ltd Company Information
- 8.4.2 Gamida Cell Ltd Business Overview
- 8.4.3 Gamida Cell Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Gamida Cell Ltd Sickle Cell Disease Drug Product Portfolio
- 8.4.5 Gamida Cell Ltd Recent Developments
- 8.5 Errant Gene Therapeutics LLC
- 8.5.1 Errant Gene Therapeutics LLC Company Information
- 8.5.2 Errant Gene Therapeutics LLC Business Overview
- 8.5.3 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Errant Gene Therapeutics LLC Sickle Cell Disease Drug Product Portfolio
- 8.5.5 Errant Gene Therapeutics LLC Recent Developments
- 8.6 Editas Medicine Inc
- 8.6.1 Editas Medicine Inc Company Information
- 8.6.2 Editas Medicine Inc Business Overview
- 8.6.3 Editas Medicine Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Editas Medicine Inc Sickle Cell Disease Drug Product Portfolio
- 8.6.5 Editas Medicine Inc Recent Developments
- 8.7 Daiichi Sankyo Co Ltd
- 8.7.1 Daiichi Sankyo Co Ltd Company Information
- 8.7.2 Daiichi Sankyo Co Ltd Business Overview
- 8.7.3 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Daiichi Sankyo Co Ltd Sickle Cell Disease Drug Product Portfolio
- 8.7.5 Daiichi Sankyo Co Ltd Recent Developments
- 8.8 CSL Ltd
- 8.8.1 CSL Ltd Company Information
- 8.8.2 CSL Ltd Business Overview
- 8.8.3 CSL Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 CSL Ltd Sickle Cell Disease Drug Product Portfolio
- 8.8.5 CSL Ltd Recent Developments
- 8.9 CRISPR Therapeutics
- 8.9.1 CRISPR Therapeutics Company Information
- 8.9.2 CRISPR Therapeutics Business Overview
- 8.9.3 CRISPR Therapeutics Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 CRISPR Therapeutics Sickle Cell Disease Drug Product Portfolio
- 8.9.5 CRISPR Therapeutics Recent Developments
- 8.10 Calimmune Inc
- 8.10.1 Calimmune Inc Company Information
- 8.10.2 Calimmune Inc Business Overview
- 8.10.3 Calimmune Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Calimmune Inc Sickle Cell Disease Drug Product Portfolio
- 8.10.5 Calimmune Inc Recent Developments
- 8.11 Bristol-Myers Squibb Co
- 8.11.1 Bristol-Myers Squibb Co Company Information
- 8.11.2 Bristol-Myers Squibb Co Business Overview
- 8.11.3 Bristol-Myers Squibb Co Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Bristol-Myers Squibb Co Sickle Cell Disease Drug Product Portfolio
- 8.11.5 Bristol-Myers Squibb Co Recent Developments
- 8.12 bluebird bio Inc
- 8.12.1 bluebird bio Inc Company Information
- 8.12.2 bluebird bio Inc Business Overview
- 8.12.3 bluebird bio Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 bluebird bio Inc Sickle Cell Disease Drug Product Portfolio
- 8.12.5 bluebird bio Inc Recent Developments
- 8.13 Bioverativ Inc
- 8.13.1 Bioverativ Inc Company Information
- 8.13.2 Bioverativ Inc Business Overview
- 8.13.3 Bioverativ Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Bioverativ Inc Sickle Cell Disease Drug Product Portfolio
- 8.13.5 Bioverativ Inc Recent Developments
- 8.14 Bio Products Laboratory Ltd
- 8.14.1 Bio Products Laboratory Ltd Company Information
- 8.14.2 Bio Products Laboratory Ltd Business Overview
- 8.14.3 Bio Products Laboratory Ltd Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Bio Products Laboratory Ltd Sickle Cell Disease Drug Product Portfolio
- 8.14.5 Bio Products Laboratory Ltd Recent Developments
- 8.15 ArQule Inc
- 8.15.1 ArQule Inc Company Information
- 8.15.2 ArQule Inc Business Overview
- 8.15.3 ArQule Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 ArQule Inc Sickle Cell Disease Drug Product Portfolio
- 8.15.5 ArQule Inc Recent Developments
- 8.16 Annexin Pharmaceuticals AB
- 8.16.1 Annexin Pharmaceuticals AB Company Information
- 8.16.2 Annexin Pharmaceuticals AB Business Overview
- 8.16.3 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 Annexin Pharmaceuticals AB Sickle Cell Disease Drug Product Portfolio
- 8.16.5 Annexin Pharmaceuticals AB Recent Developments
- 8.17 Angiocrine Bioscience Inc
- 8.17.1 Angiocrine Bioscience Inc Company Information
- 8.17.2 Angiocrine Bioscience Inc Business Overview
- 8.17.3 Angiocrine Bioscience Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 Angiocrine Bioscience Inc Sickle Cell Disease Drug Product Portfolio
- 8.17.5 Angiocrine Bioscience Inc Recent Developments
- 8.18 Addmedica SAS
- 8.18.1 Addmedica SAS Company Information
- 8.18.2 Addmedica SAS Business Overview
- 8.18.3 Addmedica SAS Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Addmedica SAS Sickle Cell Disease Drug Product Portfolio
- 8.18.5 Addmedica SAS Recent Developments
- 8.19 Acceleron Pharma Inc
- 8.19.1 Acceleron Pharma Inc Company Information
- 8.19.2 Acceleron Pharma Inc Business Overview
- 8.19.3 Acceleron Pharma Inc Sickle Cell Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Acceleron Pharma Inc Sickle Cell Disease Drug Product Portfolio
- 8.19.5 Acceleron Pharma Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Sickle Cell Disease Drug Value Chain Analysis
- 9.1.1 Sickle Cell Disease Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Sickle Cell Disease Drug Production Mode & Process
- 9.2 Sickle Cell Disease Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Sickle Cell Disease Drug Distributors
- 9.2.3 Sickle Cell Disease Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst